Clinical Trials Browser

Recruiting × ALK Positive Non-small Cell Lung Cancer × lorlatinib × Clear all

NCT06092086 2023-10-23

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Phase 2 Recruiting

ALK Positive Non-small Cell Lung Cancer